ZS Pharma, Inc.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2014 | $25 M | No. 4 | $10 to $50 million | equity | SEC | |
| Oct 2012 | $28 M | No. 3 | $10 to $50 million | equity | SEC | |
| Nov 2011 | $5 M | No. 2 | $2 to $10 million | equity, debt, options | SEC | |
| Feb 2009 | $1 M | No. 1 | Under $2 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ZS Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2014).
SEC Form D · Mar 2014
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Mar 2014
That is all the official record says: ZS Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
11 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 3x5 Special Opportunity Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Partners Management VIII, LLC | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alvaro Guillem | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Devon Park Associates, LLC | Other | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Devon Park Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Devon Park Bioventures LP | Venture capital | not stated | not stated | Held Series B, C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| D. Jeffrey Keyser | Person | not stated | not stated | Held Series A and B preferred stock, director (Form 3, 2014) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Rivervest Venture Fund II L.P. | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| RiverVest Venture Fund II (Ohio), L.P. | Venture capital | not stated | not stated | Held Series C and D preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 30 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Alvaro F. Guillem | Executive officer | Mar 2014 |
| Cynthia B. Smith | Executive officer | Mar 2014 |
| Donald Jeffrey Keyser | Executive officer | Mar 2014 |
| Henrick Sandvad Rasmussen | Executive officer | Mar 2014 |
| Robert B. Alexander | Executive officer | Mar 2014 |
| Todd B. Creech | Executive officer | Mar 2014 |
| Nels P. Bergmark | Executive officer | Oct 2012 |
| Stephen R. Ash | Executive officer | Oct 2012 |
| Alvaro F Guillem | President and CEO | Dec 2010 |
| Donald Jeffery Keyser | Chief Operating Officer | Dec 2010 |
| Joy B Barton | Chief Business Officer | Dec 2010 |
| Nels R Bergmark | Treasurer | Dec 2010 |
| Robert B Truitt | Chairman of the Board of Directors | Dec 2010 |
| Stephen R Ash | Chief Medical Officer | Dec 2010 |
| Tim B Opler | Vice President, Strategy | Dec 2010 |
| William B Kushner | Vice President, Legal Affairs | Dec 2010 |
| Alvaro F. Guillem | Director | Mar 2014 |
| Donald Jeffrey Keyser | Director | Mar 2014 |
| Guy B. Nohra | Director | Mar 2014 |
| John B. McKearn | Director | Mar 2014 |
| Marc B. Ostro | Director | Mar 2014 |
| Robert B. Alexander | Director | Mar 2014 |
| Robert B. Truitt | Director | Mar 2014 |
| Miles B. Davis | Director | Oct 2012 |
| Alvaro F Guillem | President and CEO | Dec 2010 |
| Donald Jeffery Keyser | Chief Operating Officer | Dec 2010 |
| Robert B Truitt | Chairman of the Board of Directors | Dec 2010 |
| Tim B Opler | Vice President, Strategy | Dec 2010 |